

Pfizer Quality Improvement Request for Proposals

Competitive Grant Program – using Pfizer Internal Review Process
Quality improvement strategies to enhance quality of life in ALK-positive lung cancer patients

Overview

This competitive funding call is aimed at supporting quality improvement (QI) projects that address clearly defined gaps in the non-pharmacological management of adverse events associated with ALK tyrosine kinase inhibitors (TKIs) and optimize quality of life in patients with ALK-positive (ALK+) non-small cell lung cancer (NSCLC)¹⁻⁴.

The primary objective is to promote the implementation, evaluation, and standardization of evidence-based, non-pharmacological interventions — beyond medications — within defined clinical settings (ALK+ metastatic NSCLC treated with ALK TKIs according to Spanish reimbursement and indications), to strengthen adverse event management, enhance treatment adherence, and optimize patient quality of life¹⁻⁵.

While the increased duration of treatment, enabled by targeted therapies such as ALK TKIs, has led to significant gains in disease control and survival, variability and inconsistency persist in routine clinical practice with respect to the management of cumulative adverse events^{1-4,7}. These performance gaps may contribute to reduced quality of life, avoidable treatment interruptions, and an inconsistent patient experience across care settings^{1-3,5}. For these reasons, effective management through non-pharmacological approaches is paramount to preserving treatment efficacy and ensuring a better quality of life. Existing strategies, such as patient education, structured symptom monitoring, supportive care pathways, and care coordination, are not consistently or systematically applied, thereby representing an opportunity for quality improvement^{1-3,5,6}.

Geographic Scope

Spain

Project Types and Area of Interest

Potential applicants are encouraged to identify and address the educational needs, barriers and gaps for optimizing metastatic ALK+ NSCLC patient management. This may include:

- Development and implementation of educational tools and resources for patients, caregivers, and healthcare professionals.
- Implementation of practical, non-pharmacological strategies already used or supported in clinical practice.
- Design and integration of monitoring systems, such as patient-reported outcome measures or digital tools

Key Milestones



Funding Range and Project Length

Individual projects requesting up to EUR 40,000.00 will be considered.
Maximum project length is up to 18 months.

I. Eligibility

Geographic Scope/Location of Project:

- Spain

Applicant Eligibility Criteria

- The following may apply: medical, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional organizations; government agencies; and other entities with a mission related to healthcare improvement.
- Only organizations are eligible to receive grants, not individuals.
- Collaborations within institutions (e.g., between departments and/or inter-professional), as well as between different institutions / organizations / associations, are encouraged. Please note all partners must have a relevant role and the requesting organization must have a key role in the project.
- The applicant must be the Project Lead or an authorized designee of such individual (e.g., Project Lead).
- The Project Lead must be an employee or contractor of the requesting organization.
- Requesting organization must be legally able to receive award funding directly from Pfizer International LLC. We strongly recommend that applicants confirm this with their organization or institution prior to submitting an application. Grants awarded to organizations that are subsequently found to be unable to accept funding directly from Pfizer International LLC may be subject to rescission.

II. Requirements

Primary Area of Interest:

- Oncology - Lung - QI

General Area of Interest for this RFP:

IMPORTANT: It is not our intent to support clinical research projects. Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered. Projects focused on development of new biomarker technology/techniques will not be considered.

It is our intent to support QI projects that focus on innovative and practical initiatives to improve the management of ALK TKIs related adverse events and to sustainably improve the quality of life for patients with metastatic ALK+ NSCLC. Proposals that adopt a patient-centered and pragmatic approach will be prioritized, with an emphasis on improving treatment adherence, symptom management, and overall well-being within real-world clinical settings.

Rather than developing entirely new interventions, funded projects should focus on applying existing knowledge and best practices to improve care processes related to ALK TKI treatment toxicity and the delivery of supportive care^{1-3,6}.

Proposals with a patient-centered and practical approach will be prioritized, aiming to support treatment adherence and overall well-being. Eligible projects may include initiatives that:

- Ensuring safe and consistent therapeutic management for patients with metastatic ALK+ NSCLC receiving ALK TKIs.
- Early identification and optimized management of treatment-related adverse events, including non-pharmacological interventions.
- Optimization of treatment adherence.
- Improving patient health literacy and engagement, to support self-management and shared clinical decision making.
- Enhancing communication and shared decision making among patients, healthcare providers, and multidisciplinary teams throughout the care journey.

- Improving coordination of care and implementation of care pathways, including support for patients in navigating their care and reducing avoidable complications.
- Solutions to deliver high-quality multidisciplinary care across diverse clinical practice settings.
- Multi-disciplinary collaborations are encouraged when appropriate, but all partners must have a relevant role.

It is expected that projects will be evidence-based. During review the intended outcome of the project is given careful consideration and, if appropriate based on the project goal, projects with the maximum likelihood to directly impact patient care will be given high priority. Projects including an educational element can find more information on principals of learning and behavior change for health professionals [here](#).

Target Audience

- Target applicants include healthcare professionals involved in the comprehensive management of these patients, including medical oncologists, oncology nurses, hospital pharmacists, and other supportive care professionals (such as nutritionists, physiotherapists, or psycho oncologists), who play a key role in the early identification, monitoring, and management of treatment related adverse events.

Expected Approximate Monetary Range of Grant Applications

IMPORTANT: Grants will be distributed following a fully executed agreement and submission of Final Protocol, Documentation of IRB/IEC Approval, Regulatory Approval (if applicable), Exemption or Waiver.

- **Individual projects** requesting up to **EUR 40,000.00** will be considered. The **estimated total available budget** related to this RFP is **EUR 140,000.00**.
- Award amounts include direct costs, institutional overhead costs (capped at 28% per Pfizer policy), and indirect costs.
- The amount of the grant Pfizer will be prepared to fund for any project will depend upon the expert review panel’s evaluation of the proposal and costs involved and will be stated clearly in the grant agreement.

Key Dates:



IMPORTANT: Be advised applications submitted after the due date will not be reviewed.

*Please note the deadline is 23:59 Eastern Standard Time (e.g., New York, GMT -5)

How to Submit:

IMPORTANT: Please read this section carefully since applications submitted not following these instructions will not be accepted and will be cancelled.

- Please go to www.cybergrants.com/pfizer/QI and sign in.
 - Note: there are individual portals for each grant application type. Please be sure to use the URL above.
 - First-time users should click “Create your password”.
- Click the “**Start A New Quality Improvement Grant Application**” button.
- Requirements for submission:
 - Complete all required sections of the online application
 - **IMPORTANT:** Upload proposal (see Appendix) in the Proposal/Protocol field.
- In the application:
 - For the question “**Competitive Grant?**” select “**Yes**”
 - Select the following Primary Area of Interest: **Oncology - Lung - QI**
 - Select the following Competitive Grant Program Name: **2026 Onc Spain Lung QI**

Questions:

- If you encounter any technical difficulties with the website, please click [here](#) or the “Technical Questions” link at the bottom of the page in cybergrants.
- Please click [here](#) to view “Frequently Asked Questions” regarding the Competitive Grant Program.
- If you have questions regarding this RFP, please direct them in writing to the Grant Officer, **Nicola Fenderico** (nicola.fenderico@pfizer.com), with the subject line “Quality improvement strategies to enhance quality of life in ALK-positive lung cancer patients”.

Review and Approval Process

- Grant requests received in response to a general RFP are reviewed by Pfizer to make final grant decisions.
- For selected projects: Pfizer will support only those projects for which an executed copy of the Agreement, the Protocol, and documentation of IRB/IEC approval, regulatory approval (if applicable), exemption, or waiver have been received by 01 November 2026.

Mechanism by which Applicants will be Notified:

- All applicants will be notified via email by the dates noted above.
- Applicants may be asked for additional clarification during the review period.

Grant Agreements:

- If your grant is approved, your institution will be required to enter into a written grant agreement with Pfizer. Please click [here](#) to view the core terms of the agreement.
- Under Pfizer's competitive grant program, modifications to grant agreements will not be reviewed unless a genuine conflict exists as between applicable law and the terms of the relevant grant agreement. Applicants are encouraged to share the core terms with counsel for approval prior to submitting an application.
- Except where prohibited by applicable law and, in any case, subject to review by Pfizer Legal, payment of grant funding may only be paid to the grantee organization.
- This RFP is supported by Pfizer International LLC and, if approved, the payment will be issued by a Pfizer US based legal entity.

About Pfizer Grants

Pfizer supports the global healthcare community's independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/or scientific strategies.

Pfizer's competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides details regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the research gaps as outlined in the specific RFP.

For all quality improvement grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct or monitoring of the quality improvement program.

About Pfizer QI Grants

Quality improvement (QI) projects are systematic, data-guided, sustainable activities designed to bring about immediate, positive changes in the delivery of healthcare in particular settings^{8,9}. Quality improvement seeks to standardize structure and processes to reduce variation, achieve predictable results, and improve outcomes for patients, healthcare systems, and organizations. Structure includes things like technology, culture, leadership, and physical capital. Process includes knowledge capital (e.g., standard operating procedures) or human capital (e.g., education and training)¹⁰.

QI projects systematically apply what is already known into the local practice, intended to quickly improve patient care within a specific setting. The goal of QI projects is to close a gap in performance at a specific health care system. The "performance" is a standard in health care that is not efficiently/appropriately/consistently being done¹¹. For these reasons, QI focuses on translating existing knowledge into programs or practices to immediately improve the quality of services to individuals and populations within a local institution or setting¹². The risk of participation in QI is the same as the risk of receiving standard clinical care¹³ since the standard of care remains the same for all patients.

In contrast, research projects use a systematic approach to discover something that is unknown. Research projects add new knowledge to what was previously unknown in literature through testing of a hypothesis or a scientific question¹¹. Research aims to generate knowledge with broad applications, often through controlled studies. The subjects may or may not benefit directly from the knowledge gained. Research studies aim to evaluate an innovation, study something new, or analyze a process not yet rigorously studied¹³.

References

1. Liu G, Mazieres J, Stratmann J, Felip E, Solomon BJ, Bauer TM, et al. A pragmatic guide for management of adverse events associated with lorlatinib. *Lung Cancer*. 2024;191:107535. Available from: [https://www.lungcancerjournal.info/article/S0169-5002\(24\)00068-0/fulltext](https://www.lungcancerjournal.info/article/S0169-5002(24)00068-0/fulltext)
2. Arriola E, de Castro J, García-Campelo R, Bernárdez B, Bernabé R, Bruna J, et al. Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer. *Clin Drug Investig*. 2024;44:553–576. Available from: <https://link.springer.com/article/10.1007/s40261-024-01379-7>
3. Zhou F, Yang Y, Zhang L, Dong X, Zhu B, Zhou C, et al. Expert consensus of management of adverse drug reactions with anaplastic lymphoma kinase tyrosine kinase inhibitors. *ESMO Open*. 2023;8(3):101560. Available from: [https://www.esmooopen.com/article/S2059-7029\(23\)00786-X/fulltext](https://www.esmooopen.com/article/S2059-7029(23)00786-X/fulltext)
4. Huang Y, Chu Q, Wang J, Zhang L. Health-related quality of life among anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) patients treated with first- and next-generation ALK tyrosine kinase inhibitors (TKIs): a systematic review and meta-analysis. *Qual Life Res*. 2025;34:3073–3092. Available from: <https://link.springer.com/article/10.1007/s11136-025-04088-6>
5. Billings NE, van den Hurk CJG, Tromp VNM, et al. Patient- vs Physician-Initiated Response to Symptom Monitoring and Health-Related Quality of Life: The SYMPRO-Lung Cluster Randomized Trial. *JAMA Netw*

Open. 2024;7(8):e2428975. Available from:
<https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2822808>

6. European Society for Medical Oncology (ESMO). ESMO Clinical Practice Guidelines: Supportive and Palliative Care. ESMO; (accessed 2026 Feb 16). Available from: <https://cdn.esmo.org/guidelines/esmo-clinical-practice-guidelines-supportive-and-palliative-care>
7. Arnaoutakis K, Wan Y, Elliott J, Young M, Yin Y, Leventakos K, et al. Real-World Treatment Patterns and Outcomes Across Three Lines of Therapy in Patients with ALK+ NSCLC. *Adv Ther*. 2024;41:3217–3231. Available from: <https://link.springer.com/article/10.1007/s12325-024-02899-6>
8. Baily MA, et al., *Hastings Cent Rep*, 2006.
9. Lynn J, et al., *Ann Intern Med*, 2007.
10. Centers for Medicare & Medicaid Services, Page Last Modified: 09/10/2024.
11. Jackson C, Research Quality Manager, Office of Research and Scholarship University of Maryland, Baltimore School of Nursing.
12. Columbia University Institutional Review Board Guidance for the Classification of Quality Improvement Activities Versus Research with human Subjects, 2023.
13. Newhouse et al., *J Nurs Adm*, 2006.ibliography of relevant references.

Appendix

IMPORTANT: RFP Submission Requirements

Applications will be accepted via the online portal listed in the How to Submit section. Project Proposals/Protocols should be single-spaced using Calibri 12-point font and 1-inch margins. Note there is a 15-page limit exclusive of references. When uploading your Full Proposal please ensure it addresses the following sections:

Goals and Objectives

- Briefly state the overall goal of the project. Also describe how this goal aligns with the focus of the RFP and the goals of the applicant organization(s).
- List the overall objectives you plan to meet with your project both in terms of learning and expected outcomes. Objectives should describe the target population as well as the outcomes you expect to achieve as a result of conducting the project.

Assessment of Need for the Project

- Please include a quantitative baseline data summary, initial metrics (e.g., quality measures), or a project starting point (please cite data on gap analyses or relevant patient-level data that informs the stated objectives) in your target area. Describe the source and method used to collect the data. Describe how the data was analyzed to determine that a gap existed. If a full analysis has not yet been conducted, please include a description of your plan to obtain this information.

Target Audience

- Describe the primary audience(s) targeted for this project. Also indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population

Project Design and Methods

- Describe the planned project and the way it addresses the established need.
- If your methods include educational activities, please describe succinctly the topic(s) and format of those activities.

Innovation

- Explain what measures you have taken to assure that this project idea is original and does not duplicate other projects or materials already developed.
- Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions related to this project.

Evaluation and Outcomes

- In terms of the metrics used for the needs assessment, describe how you will determine if the practice gap was addressed for the target group. Describe how you expect to collect and analyze the data.
- Quantify the amount of change expected from this project in terms of your target audience.
- Describe how the project outcomes will be broadly disseminated.

Anticipated Project Timeline

- Provide an anticipated timeline for your project including project start/end dates.

Additional Information

- If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize here.

Organization Detail

- Describe the attributes of the institutions / organizations / associations that will support and facilitate the execution of the project and the leadership of the proposed project. Articulate the specific role of each partner in the proposed project.

Budget Detail

- The budget amount requested must be in EUR.
- While estimating your budget please keep the following items in mind:
 - General organizational running costs such as legal fees, insurance, heating, and lighting etc. should be included in an Institutional Overhead (if required). These costs are not specific to a grant request and therefore, should not appear as line items in budgets. However, costs that are specific to the study (e.g., some countries require insurance to be taken out on a per-study basis for clinical research) would be acceptable to be included as line items.
 - The inclusion of these costs cannot cause the amount requested to exceed the budget limit set forth in the RFP.
 - Pfizer does not provide funding for capital purchases (infrastructure expenses such as equipment, purchases of software or software licenses, technology or bricks and mortar). Equipment hire/leasing is acceptable and may be included in project budget.
It should be noted that grants awarded through ER&G cannot be used to purchase Pfizer therapeutic agents (prescription or non-prescription).
- Pfizer maintains a company-wide, maximum allowed overhead rate of 28% for independent studies and projects. Please [click here](#) for details.

Required Documents

- Project Plan or Proposal